{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T15:52:24Z","timestamp":1790351544543,"version":"4.1.0"},"reference-count":35,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,6,14]],"date-time":"2021-06-14T00:00:00Z","timestamp":1623628800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["esmoopen.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["ESMO Open"],"published-print":{"date-parts":[[2021,8]]},"DOI":"10.1016\/j.esmoop.2021.100203","type":"journal-article","created":{"date-parts":[[2021,7,13]],"date-time":"2021-07-13T05:34:24Z","timestamp":1626154464000},"page":"100203","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":26,"title":["Detection of secondary metastatic breast cancer by measurement of plasma CA 15.3"],"prefix":"10.1016","volume":"6","author":[{"given":"L.","family":"De Cock","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Heylen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Wildiers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Punie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Smeets","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Weltens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Neven","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Billen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Laenen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Wildiers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.esmoop.2021.100203_bib1","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1093\/annonc\/mdz173","article-title":"Early breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"30","author":"Cardoso","year":"2019","journal-title":"Ann Oncol"},{"key":"10.1016\/j.esmoop.2021.100203_bib2","doi-asserted-by":"crossref","first-page":"5287","DOI":"10.1200\/JCO.2007.14.2364","article-title":"American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer","volume":"25","author":"Harris","year":"2007","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.esmoop.2021.100203_bib3","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1200\/JCO.2012.45.9859","article-title":"Breast cancer follow-up and management after primary treatment: American Society of Clinical Oncology clinical practice guideline update","volume":"31","author":"Khatcheressian","year":"2013","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.esmoop.2021.100203_bib4","doi-asserted-by":"crossref","first-page":"4316","DOI":"10.1002\/cncr.28363","article-title":"Use of imaging and biomarker tests for posttreatment care of early-stage breast cancer survivors","volume":"119","author":"Hahn","year":"2013","journal-title":"Cancer"},{"key":"10.1016\/j.esmoop.2021.100203_bib5","doi-asserted-by":"crossref","first-page":"dju034","DOI":"10.1093\/jnci\/dju034","article-title":"Promoting quality and evidence-based care in early-stage breast cancer follow-up","volume":"106","author":"Henry","year":"2014","journal-title":"J\u00a0Natl Cancer Inst"},{"key":"10.1016\/j.esmoop.2021.100203_bib6","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1200\/JCO.2014.55.5409","article-title":"Tumor marker usage and medical care costs among older early-stage breast cancer survivors","volume":"33","author":"Ramsey","year":"2015","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.esmoop.2021.100203_bib7","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1200\/JCO.2006.08.6876","article-title":"Surveillance testing among survivors of early-stage breast cancer","volume":"25","author":"Keating","year":"2007","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.esmoop.2021.100203_bib8","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1373\/clinchem.2005.059832","article-title":"Serum tumor markers in breast cancer: are they of clinical value?","volume":"52","author":"Duffy","year":"2006","journal-title":"Clin Chem"},{"key":"10.1016\/j.esmoop.2021.100203_bib9","first-page":"498","volume":"58","author":"Wojtacki","year":"2001","journal-title":"Przegl Lek"},{"key":"10.1016\/j.esmoop.2021.100203_bib10","doi-asserted-by":"crossref","first-page":"1869","DOI":"10.1016\/j.cca.2010.08.039","article-title":"CA 15-3: uses and limitation as a biomarker for breast cancer","volume":"411","author":"Duffy","year":"2010","journal-title":"Clin Chim Acta"},{"key":"10.1016\/j.esmoop.2021.100203_bib11","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1007\/s10549-005-5199-2","article-title":"Follow-up cost of breast cancer patients with localized disease after primary treatment: a randomized trial","volume":"93","author":"Kokko","year":"2005","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.esmoop.2021.100203_bib12","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1007\/BF02303645","article-title":"Evaluation of an intensive strategy for follow-up and surveillance of primary breast cancer","volume":"5","author":"Joseph","year":"1998","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.esmoop.2021.100203_bib13","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1016\/S0959-8049(01)00429-4","article-title":"Ca 15-3 in the follow-up of localised breast cancer: a prospective study","volume":"38","author":"Kokko","year":"2002","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.esmoop.2021.100203_bib14","doi-asserted-by":"crossref","first-page":"232","DOI":"10.3892\/mco.2014.419","article-title":"Association of CA 15-3 and CEA with clinicopathological parameters in patients with metastatic breast cancer","volume":"3","author":"Geng","year":"2015","journal-title":"Mol Clin Oncol"},{"key":"10.1016\/j.esmoop.2021.100203_bib15","first-page":"850","article-title":"Symptomatic metastasis prediction with serial measurements of CA 15.3 in primary breast cancer patients","volume":"17","author":"Bahrami-Ahmadi","year":"2012","journal-title":"J\u00a0Res Med Sci"},{"key":"10.1016\/j.esmoop.2021.100203_bib16","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1177\/172460080201700403","article-title":"Prognostic value of CA 15.3 kinetics for metastatic breast cancer","volume":"17","author":"De La Lande","year":"2002","journal-title":"Int J Biol Markers"},{"key":"10.1016\/j.esmoop.2021.100203_bib17","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1159\/000089260","article-title":"Tumor markers in breast cancer- European Group on Tumor Markers recommendations","volume":"26","author":"Molina","year":"2005","journal-title":"Tumour Biol"},{"key":"10.1016\/j.esmoop.2021.100203_bib18","first-page":"5179","article-title":"Serial CEA and CA 15-3 measurements during follow-up of breast cancer patients","volume":"20","author":"Jager","year":"2000","journal-title":"Anticancer Res"},{"key":"10.1016\/j.esmoop.2021.100203_bib19","series-title":"Cancer Staging Manual","author":"Amin","year":"2018"},{"key":"10.1016\/j.esmoop.2021.100203_bib20","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1200\/JCO.19.02309","article-title":"Estrogen and progesterone receptor testing in breast cancer: ASCO\/CAP Guideline Update","volume":"38","author":"Allison","year":"2020","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.esmoop.2021.100203_bib21","doi-asserted-by":"crossref","first-page":"34","DOI":"10.4132\/jptm.2019.11.03","article-title":"HER2 status in breast cancer: changes in guidelines and complicating factors for interpretation","volume":"54","author":"Ahn","year":"2020","journal-title":"J\u00a0Pathol Transl Med"},{"key":"10.1016\/j.esmoop.2021.100203_bib22","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1186\/s13058-017-0909-3","article-title":"Reproductive profiles and risk of breast cancer subtypes: a multi-center case-only study","volume":"19","author":"Brouckaert","year":"2017","journal-title":"Breast Cancer Res"},{"key":"10.1016\/j.esmoop.2021.100203_bib23","doi-asserted-by":"crossref","first-page":"2206","DOI":"10.1093\/annonc\/mdt303","article-title":"Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013","volume":"24","author":"Goldhirsch","year":"2013","journal-title":"Ann Oncol"},{"key":"10.1016\/j.esmoop.2021.100203_bib24","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2174\/1876817201305010001","article-title":"Clinical usefulness of cancer antigen 15-3 in breast cancer patients before and after surgery","volume":"5","author":"Daniele","year":"2013","journal-title":"Open Breast Cancer J"},{"key":"10.1016\/j.esmoop.2021.100203_bib25","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1007\/s10549-010-1117-3","article-title":"Clinical significance of a serum CA 15-3 surge and the usefulness of CA 15-3 kinetics in monitoring chemotherapy response in patients with metastatic breast cancer","volume":"124","author":"Wu","year":"2010","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.esmoop.2021.100203_bib26","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1007\/s10549-009-0377-2","article-title":"Clinical significance of a serum CA15-3 surge and the usefulness of CA15-3 kinetics in monitoring chemotherapy response in patients with metastatic breast cancer","volume":"118","author":"Kim","year":"2009","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.esmoop.2021.100203_bib27","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.1002\/cncr.20581","article-title":"The neutrophil, not the tumor: serum CA 15-3 elevation as a result of granulocyte--colony-stimulating factor-induced neutrophil MU1C overexpression and neutrophilia in patients with breast carcinoma receiving adjuvant chemotherapy","volume":"101","author":"Pentheroudakis","year":"2004","journal-title":"Cancer"},{"key":"10.1016\/j.esmoop.2021.100203_bib28","doi-asserted-by":"crossref","first-page":"5954","DOI":"10.21037\/apm-20-1128","article-title":"Oligometastatic breast cancer: where are we now and where are we headed?-A narrative review","volume":"10","author":"Kent","year":"2021","journal-title":"Ann Palliat Med"},{"key":"10.1016\/j.esmoop.2021.100203_bib29","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1038\/bjc.1996.501","article-title":"Utility of C-erbB-2 in tissue and in serum in the early diagnosis of recurrence in breast cancer patients: comparison with carcinoembryonic antigen and CA 15.3","volume":"74","author":"Molina","year":"1996","journal-title":"Br J Cancer"},{"key":"10.1016\/j.esmoop.2021.100203_bib30","first-page":"923","article-title":"[Prevalence of elevated serum CA 15-3 at time of metastatic relapse of breast cancer and correlation with hormone receptor status]","volume":"96","author":"Bensouda","year":"2009","journal-title":"Bull Cancer"},{"key":"10.1016\/j.esmoop.2021.100203_bib31","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1159\/000336081","article-title":"Implications of different CA 15-3 levels according to breast Cancer subtype at initial diagnosis of recurrent or metastatic breast cancer","volume":"82","author":"Park","year":"2012","journal-title":"Oncology"},{"key":"10.1016\/j.esmoop.2021.100203_bib32","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1093\/annonc\/mdr154","article-title":"Tumor markers in metastatic breast cancer subtypes: frequency of elevation and correlation with outcome","volume":"23","author":"Yerushalmi","year":"2012","journal-title":"Ann Oncol"},{"key":"10.1016\/j.esmoop.2021.100203_bib33","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1007\/s10549-020-05847-4","article-title":"Patterns in detection of recurrence among patients treated for breast cancer","volume":"184","author":"Saltb\u00e6k","year":"2020","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.esmoop.2021.100203_bib34","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/bs.pmbts.2019.01.005","article-title":"Serum CA153 as biomarker for cancer and noncancer diseases","volume":"162","author":"Li","year":"2019","journal-title":"Prog Mol Biol Transl Sci"},{"key":"10.1016\/j.esmoop.2021.100203_bib35","doi-asserted-by":"crossref","first-page":"4255","DOI":"10.1158\/1078-0432.CCR-18-3663","article-title":"Personalized detection of circulating tumor DNA antedates breast cancer metastatic recurrence","volume":"25","author":"Coombes","year":"2019","journal-title":"Clin Cancer Res"}],"container-title":["ESMO Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702921001642?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702921001642?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T20:27:58Z","timestamp":1761856078000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2059702921001642"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8]]},"references-count":35,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021,8]]}},"alternative-id":["S2059702921001642"],"URL":"https:\/\/doi.org\/10.1016\/j.esmoop.2021.100203","relation":{},"ISSN":["2059-7029"],"issn-type":[{"value":"2059-7029","type":"print"}],"subject":[],"published":{"date-parts":[[2021,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Detection of secondary metastatic breast cancer by measurement of plasma CA 15.3","name":"articletitle","label":"Article Title"},{"value":"ESMO Open","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.esmoop.2021.100203","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Author(s). Published by Elsevier Ltd on behalf of European Society for Medical Oncology.","name":"copyright","label":"Copyright"}],"article-number":"100203"}}